Pharmacogenomic impact and genetic architecture of toxicity in pediatric acute lymphoblastic leukemia induction therapy: an exploratory modeling approach.

Front Pharmacol · 2026 · PMC13314868 · PMID 42382175

Europe PMC DOI

hedged sentence

0.0060

closest p · 0.1× alpha

0.0060

boldest claim

The sentences

nominally significantp = 0.006actually significant

We observed several complex interactions, notably suggesting an increased risk of severe neutropenia in patients carrying a homozygous variant CYP3A5 rs776746 genotype (nominally significant OR 5.58, p = 0.006) and a potential pleiotropic protective effect from NFATC2 rs6021191 (OR 0.09, p = 0.001).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.